CMD-501

We are developing CMD-501 for the treatment of neuroblastoma and small cell lung cancer. CMD-501 is an autologous cell therapy which utilizes our natural killer T (NKT) cell platform technology in combination with genetically engineered chimeric antigen receptors (CARs) and secretion of the IL-15 cytokine to sustain the activity of the therapeutic cells within the immunosuppressive tumor microenvironment. The product is currently in pre-clinical development with the Phase 1 study planned for Q2 2018.

Eligible patient population

Neuroblastoma – Neuroblastoma affects around 1,600 children each year in the United States1 and Europe2 combined.  Similar incidence rates are observed in other regions of the developed world.

Small cell lung cancer – Lung cancer is one of the most common cancers worldwide, responsible for 1.8 million new patients every year and 1.63 million deaths. Most lung cancers are non-small cell lung cancers (NSCLC).  Small cell lung cancer (SCLC) is less frequent and is responsible for about 15%4 of all newly diagnosed lung cancers.   CMD-501 will target about 50% of small cell lung cancer patients based upon the specific targeted cancer antigen (undisclosed).

The development of CMD-501

We are developing CMD-501 in neuroblastoma as the lead indication and proof of concept.  We will then broaden the application of CMD-501 to the lung cancer indication.

.